What is Elicio Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Elicio Therapeutics's interest expense for the
three
months ended in Mar. 2024 was $ -0.04 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.75 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Elicio Therapeutics's Operating Income for the
three
months ended in Mar. 2024 was $ -10.24 Mil. Elicio Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $ -0.04 Mil.
Elicio Therapeutics did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Elicio Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elicio Therapeutics (NAS:ELTX) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Elicio Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $-0.04 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-10.24 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $5.79 Mil.
Elicio Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| Elicio Therapeutics did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Elicio Therapeutics (Elicio Therapeutics) Business Description
Traded in Other Exchanges
Address
One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA, USA, 02139
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.
Executives
| Yekaterina Chudnovsky |
director |
C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
| Robert R Ruffolo |
director |
|
| Peter Demuth |
officer: Chief Scientific Officer |
C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
| Assaf Segal |
director |
C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
| Annette Matthies |
officer: Chief Business Officer |
ONE KENDALL SQUARE, BUILDING 1400 WEST, SUITE 14303, CAMBRIDGE MA 02139 |
| Robert Connelly |
director, officer: CEO, President and Director |
1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102 |
| Julian Adams |
director |
C/O GAMIDA CELL, 673 BOYLSTON STREET, 4TH FLOOR, BOSTON MA 02116 |
| Christopher Haqq |
officer: See Remarks |
C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
| Carol Gail Ashe |
director |
C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3 |
| Brian Piekos |
officer: Chief Financial Officer |
C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
| Karen J Wilson |
director |
C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
| Gilbert S Omenn |
director |
AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
| Gregory S Curhan |
officer: See Remarks |
600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108 |
| Itzhak Goldberg |
officer: See Remarks |
51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553 |
| John F. Neylan |
officer: See Remarks |
750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Elicio Therapeutics (Elicio Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELTX has been successfully added to your 